Cargando…
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813251/ https://www.ncbi.nlm.nih.gov/pubmed/35126664 http://dx.doi.org/10.1155/2022/8537966 |
_version_ | 1784644808259665920 |
---|---|
author | Bian, Jin Niu, Yan Ma, Yanli Chen, Fuhua Ma, Ning |
author_facet | Bian, Jin Niu, Yan Ma, Yanli Chen, Fuhua Ma, Ning |
author_sort | Bian, Jin |
collection | PubMed |
description | Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC. |
format | Online Article Text |
id | pubmed-8813251 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-88132512022-02-04 A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy Bian, Jin Niu, Yan Ma, Yanli Chen, Fuhua Ma, Ning Appl Bionics Biomech Research Article Epstein-Barr virus (EBV) linked with nasopharyngeal carcinoma (NPC) is considered to be one of the most prevalent head and neck malignancies in East and Southeast Asia. Although radiotherapy and chemotherapy are effective treatments for NPC, they have immunosuppressive effects. Immunotherapy has got considerable attention of clinicians for cancer treatment in recent years due to proven success of PD-1/PD-L 1 inhibition in solid tumors trials. The distinct immunological environment of EBV-associated NPC presents a reasonable therapeutic target for PD-1/PD-L 1 inhibition. Immune checkpoint blockade therapy targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L 1) receptors have shown efficacy in early phase I clinical trials, with ongoing phase III clinical trials. Herein, we have extensively addressed the role of the PD-1/PD-L1 axis in the immunotherapy of EBV-associated NPC. Immunotherapeutic strategies are anticipated to enter mainstream clinical practise and provide long-term remissions in patients with severe NPC. Hindawi 2022-01-27 /pmc/articles/PMC8813251/ /pubmed/35126664 http://dx.doi.org/10.1155/2022/8537966 Text en Copyright © 2022 Jin Bian et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bian, Jin Niu, Yan Ma, Yanli Chen, Fuhua Ma, Ning A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title_full | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title_fullStr | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title_full_unstemmed | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title_short | A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy |
title_sort | review on the application of pd-1 blockade in ebv-associated nasopharyngeal carcinoma immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813251/ https://www.ncbi.nlm.nih.gov/pubmed/35126664 http://dx.doi.org/10.1155/2022/8537966 |
work_keys_str_mv | AT bianjin areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT niuyan areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT mayanli areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT chenfuhua areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT maning areviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT bianjin reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT niuyan reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT mayanli reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT chenfuhua reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy AT maning reviewontheapplicationofpd1blockadeinebvassociatednasopharyngealcarcinomaimmunotherapy |